[go: up one dir, main page]

ATE530546T1 - Kokristalle und pharmazeutische zusammensetzungen damit - Google Patents

Kokristalle und pharmazeutische zusammensetzungen damit

Info

Publication number
ATE530546T1
ATE530546T1 AT08829433T AT08829433T ATE530546T1 AT E530546 T1 ATE530546 T1 AT E530546T1 AT 08829433 T AT08829433 T AT 08829433T AT 08829433 T AT08829433 T AT 08829433T AT E530546 T1 ATE530546 T1 AT E530546T1
Authority
AT
Austria
Prior art keywords
cocrystals
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
AT08829433T
Other languages
English (en)
Inventor
Yuegang Zhang
Patrick Connelly
Steve Johnston
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE530546T1 publication Critical patent/ATE530546T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08829433T 2007-08-30 2008-08-29 Kokristalle und pharmazeutische zusammensetzungen damit ATE530546T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96902307P 2007-08-30 2007-08-30
PCT/US2008/010254 WO2009032198A1 (en) 2007-08-30 2008-08-29 Co-crystals and pharmaceutical compositions comprising the same

Publications (1)

Publication Number Publication Date
ATE530546T1 true ATE530546T1 (de) 2011-11-15

Family

ID=40011185

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08829433T ATE530546T1 (de) 2007-08-30 2008-08-29 Kokristalle und pharmazeutische zusammensetzungen damit

Country Status (13)

Country Link
US (1) US8492546B2 (de)
EP (2) EP2185546B1 (de)
JP (1) JP5443360B2 (de)
CN (1) CN101835774B (de)
AR (1) AR068817A1 (de)
AT (1) ATE530546T1 (de)
AU (1) AU2008297015B2 (de)
CA (1) CA2704284A1 (de)
CL (1) CL2008002549A1 (de)
MX (1) MX2010002407A (de)
NZ (1) NZ583699A (de)
TW (1) TW200922933A (de)
WO (1) WO2009032198A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
RU2011112802A (ru) * 2008-09-03 2012-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Сокристаллы и содержащие их фармацевтические композиции
BR112012010597B8 (pt) * 2009-11-06 2022-07-19 Basf Se Complexo cristalino, processo para preparar o complexo cristalino, formulação agrícola, método para controlar fungos fitopatogênicos, método para melhorar a saúde de plantas, método para a proteção de material de propagação de planta contra pragas, método para regular o crescimento de plantas e material de propagação de planta revestido
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
EP2935245A1 (de) * 2012-12-21 2015-10-28 Sandoz AG Neuartige formen von telaprevir
CN103497234B (zh) * 2013-09-24 2015-07-08 苏州永健生物医药有限公司 一种特拉匹韦中间体a晶型及其合成方法
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2020025781A1 (en) 2018-08-03 2020-02-06 Center For Intelligent Research In Crystal Engineering, S.L. Cocrystals of ubiquinone and compositions comprising them

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5496927A (en) 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
ATE71934T1 (de) 1985-06-07 1992-02-15 Ici America Inc Selektionierte difluorverbindungen.
US5231084A (en) 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
US5736520A (en) 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
US5371072A (en) 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
EP0604182B1 (de) 1992-12-22 2000-10-11 Eli Lilly And Company HIV Protease hemmende Verbindungen
EP0674513B1 (de) 1992-12-29 1996-09-25 Abbott Laboratories Inhibitoren der retroviralen protease
US5384410A (en) 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
US5656600A (en) 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
RU95104898A (ru) 1994-03-31 1996-12-27 Бристоль-Мейерз Сквибб Компани (US) Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JP2000500760A (ja) 1995-11-23 2000-01-25 メルク シヤープ エンド ドーム リミテツド スピロピペリジン誘導体およびタキキニン拮抗薬としてのその使用
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
ATE320432T1 (de) 1996-09-25 2006-04-15 Merck Sharp & Dohme Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
CA2268255A1 (en) 1996-10-08 1998-04-16 Colorado State University Research Foundation Catalytic asymmetric epoxidation
BR9712544B1 (pt) 1996-10-18 2013-10-22 Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
DE19648011A1 (de) 1996-11-20 1998-05-28 Bayer Ag Cyclische Imine
EP0966465B1 (de) 1997-03-14 2003-07-09 Vertex Pharmaceuticals Incorporated Inhibitoren des impdh-enzyms
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
GB9711114D0 (en) 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
US6183121B1 (en) 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999028482A2 (en) 1997-11-28 1999-06-10 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
EP1066247B1 (de) 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitoren von serin proteasen, insbesondere von hepatitis c virus ns3 protease
US6251583B1 (en) 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
US6117639A (en) 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
US6025516A (en) 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
US20020042046A1 (en) 1999-02-25 2002-04-11 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
AU769383B2 (en) 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
US20020183249A1 (en) 1999-08-31 2002-12-05 Taylor Neil R. Method of identifying inhibitors of CDC25
EP1252178A1 (de) 1999-12-03 2002-10-30 Bristol-Myers Squibb Pharma Company Alapha-ketoamid inhibitoren der hepatitis c virus ns3 protease
WO2001064678A2 (en) 2000-02-29 2001-09-07 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
CA2405043A1 (en) 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AU2001253124A1 (en) 2000-04-05 2001-10-23 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
IL151935A0 (en) 2000-04-19 2003-04-10 Schering Corp Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
US7419678B2 (en) 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
EP2289888A3 (de) 2000-06-30 2011-07-13 Seikagaku Corporation Epoxidcarboxylsäureamide, Azide und Aminoalkohole sowie Verfahren zur Herstellung von Alpha-Ketoamiden damit
MY143322A (en) 2000-07-21 2011-04-15 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
MXPA03000626A (es) 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2001277967A1 (en) 2000-07-21 2002-02-05 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
EP1337550B1 (de) 2000-11-20 2006-05-24 Bristol-Myers Squibb Company Hepatitis c tripeptid inhibitoren
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
EP1539188B1 (de) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nukleosidderivate als inhibitoren der rna-abhängigen viralen rna-polymerase
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US20020187488A1 (en) 2001-01-30 2002-12-12 Chao Lin Quantitative assay for nucleic acids
ATE431396T1 (de) 2001-03-27 2009-05-15 Vertex Pharma Für hcv-infektion geeignete zusammensetzungen und verfahren
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
MXPA04000293A (es) 2001-07-11 2004-05-04 Vertex Pharma Inhibidores de serina proteasa biciclica de puente.
JP2003055389A (ja) 2001-08-09 2003-02-26 Univ Tokyo 錯体及びそれを用いたエポキシドの製法
DE10140234A1 (de) * 2001-08-22 2003-03-13 Karmann Gmbh W Cabriolet-Fahrzeug mit einem zumindest bereichsweise flexiblen Dach
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
US20030229390A1 (en) 2001-09-17 2003-12-11 Control Delivery Systems, Inc. On-stent delivery of pyrimidines and purine analogs
AU2002348414B2 (en) 2001-10-24 2009-10-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
ES2234451T1 (es) 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
RU2004133044A (ru) 2002-04-11 2006-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы сериновых протеаз, в частности, протеазы ns3-ns4a hcv
US20030204168A1 (en) 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US6835387B2 (en) 2002-06-11 2004-12-28 Scimed Life Systems, Inc. Sustained release of superoxide dismutase mimics from implantable or insertable medical devices
SG174624A1 (en) 2002-08-01 2011-10-28 Pharmasset Inc Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
JP4027751B2 (ja) 2002-08-23 2007-12-26 横浜ゴム株式会社 タイヤ用ホイールセット及びそれを装着した車両
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US6715452B1 (en) 2002-11-13 2004-04-06 Arvin Technologies, Inc. Method and apparatus for shutting down a fuel reformer
CA2413705A1 (en) 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
CA2516328A1 (en) 2003-02-18 2004-09-02 Pfizer Inc. Inhibitors of hepatitis c virus, compositions and treatments using the same
WO2004101602A2 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
EP1613620A1 (de) 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitoren von serinproteasen, insbesondere hcv-ns3-ns4a-protease
CN100453553C (zh) 2003-04-11 2009-01-21 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
EP1654261B1 (de) 2003-05-21 2007-11-14 Boehringer Ingelheim International GmbH Verbindungen als hepatitis c inhibitoren
TW200523270A (en) 2003-07-18 2005-07-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
WO2005012911A1 (en) * 2003-07-29 2005-02-10 Solvay Pharmaceuticals Gmbh Analytical method for pancreatin and comparable compositions
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
TW200528472A (en) 2003-10-10 2005-09-01 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
AU2004285019B9 (en) 2003-10-27 2011-11-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
ES2319775T3 (es) 2003-10-27 2009-05-12 Vertex Pharmaceuticals Incorporated Combinaciones para el tratamiento del vhc.
US7250520B2 (en) 2003-10-28 2007-07-31 Vertex Pharmaceuticals Incorporated Processes for preparing pyrroles
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20050287514A1 (en) 2003-12-01 2005-12-29 Vertex Pharmaceuticals Incorporated Compositions and methods useful for HCV infection
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
EP2311851A3 (de) 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitoren der Serinproteasen, insbesondere der HCV-NS3-NS4A-Protease
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
EA200901463A1 (ru) 2004-02-20 2010-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
AR048413A1 (es) 2004-02-27 2006-04-26 Schering Corp Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c
KR20110137409A (ko) 2004-03-12 2011-12-22 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한 방법 및 중간체
US20050249702A1 (en) 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
AR049297A1 (es) * 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
EP1604697A1 (de) 2004-06-09 2005-12-14 J.A.C.C. GmbH Implantierbare Vorrichtung
EP1765379A4 (de) * 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc Pharmazeutische ko-kristallzusammensetzungen und relevante anwendungsverfahren
CA2577812A1 (en) 2004-08-27 2006-03-09 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
KR20130083938A (ko) 2004-10-01 2013-07-23 버텍스 파마슈티칼스 인코포레이티드 Ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제 저해
TW201424733A (zh) 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
US7935140B2 (en) 2005-05-13 2011-05-03 Merit Medical Systems, Inc. Delivery device with anchoring features and associated method
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
EP2256113A1 (de) 2005-08-02 2010-12-01 Vertex Pharmaceuticals Incorporated Serinprotease-Hemmer
BRPI0615029A2 (pt) 2005-08-19 2009-06-16 Vertex Pharma processos e intermediários
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP1933894A2 (de) 2005-09-06 2008-06-25 Light Sciences Oncology, Inc. Implantierbare vorrichtung zur therapeutischen behandlung in einem körperlumen
AU2006289626A1 (en) * 2005-09-09 2007-03-15 Universitat Zurich Antigens for vaccination against and detection of Mycoplasma suis
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP2194039A1 (de) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Verfahren zur Herstellung optisch aktiver Verbindungen
AU2007227580A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
JP2009530416A (ja) 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬組成物
WO2007109604A2 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US20100003634A1 (en) 2006-04-25 2010-01-07 D B Orthodontics Ltd Orthodontic implant device
EP2020956A2 (de) 2006-05-26 2009-02-11 Nanyang Technological University Implantierbarer artikel, verfahren zu seiner herstellung sowie verfahren zur verminderung von thrombogenität
PL2037887T3 (pl) 2006-05-31 2011-03-31 Vertex Pharma Doustne preparaty o kontrolowanym uwalnianiu inhibitora enzymu konwertującego interleukinę 1 beta
EP2077797A4 (de) 2006-08-28 2010-07-21 Cornova Inc Implantierbare produkte und verfahren zu ihrer bildung
EP2114506A4 (de) 2007-02-09 2014-11-05 Taheri Laduca Llc Vorrichtung und verfahren zum einsatz einer implantierbaren vorrichtung im körper

Also Published As

Publication number Publication date
US8492546B2 (en) 2013-07-23
JP2010537987A (ja) 2010-12-09
TW200922933A (en) 2009-06-01
AU2008297015B2 (en) 2013-08-22
EP2185546B1 (de) 2011-10-26
CA2704284A1 (en) 2009-03-12
WO2009032198A1 (en) 2009-03-12
EP2436682A1 (de) 2012-04-04
CN101835774A (zh) 2010-09-15
AR068817A1 (es) 2009-12-09
AU2008297015A1 (en) 2009-03-12
CL2008002549A1 (es) 2010-09-03
EP2185546A1 (de) 2010-05-19
CN101835774B (zh) 2014-09-17
US20110009424A1 (en) 2011-01-13
NZ583699A (en) 2012-04-27
MX2010002407A (es) 2010-03-26
JP5443360B2 (ja) 2014-03-19

Similar Documents

Publication Publication Date Title
ATE542815T1 (de) Kokristalle und pharmazeutische zusammensetzungen damit
ATE530546T1 (de) Kokristalle und pharmazeutische zusammensetzungen damit
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
EP1992348A4 (de) Pharmazeutische kombination
LTC2140867I2 (lt) Farmacinė kompozicija
DK2343071T3 (da) Farmaceutiske doseringsformer
PL2152237T3 (pl) Nowa kompozycja farmaceutyczna
ATE493119T1 (de) Pharmazeutische zusammensetzung
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI0923836A2 (pt) Composições farmacêuticas orais contendo opióide e métodos
EP2413693A4 (de) Substituierte azoanthrazenderivate sowie pharmazeutische zusammensetzungen damit und verwendungsverfahren dafür
DK1884242T3 (da) Farmaceutisk sammensætning omfattende lurasidon
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
LTC2502996I2 (lt) Anti-FGF23 antikūnas ir jį apimanti farmacinė kompozicija
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0817833A2 (pt) Composição farmacêutica antimalárica
EP2341047A4 (de) Cyclohexanderivat und pharmazeutische anwendung davon
DE602008005137D1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
DK1957073T3 (da) Lægemiddel
EP2193795A4 (de) Latanoprosthaltige wässrige pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties